BSX Boston Scientific Corp

Price (delayed)

$46.6

Market cap

$66.75B

P/E Ratio

113.66

Dividend/share

N/A

EPS

$0.41

Enterprise value

$74.99B

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, ...

Highlights
Boston Scientific's gross profit has increased by 12% YoY
The revenue has increased by 10% YoY
BSX's quick ratio is down by 31% year-on-year but it is up by 11% since the previous quarter
The P/E is 48% above the last 4 quarters average of 76.6 and 24% above the 5-year quarterly average of 91.5
The EPS has decreased by 47% YoY and by 28% from the previous quarter

Key stats

What are the main financial stats of BSX
Market
Shares outstanding
1.43B
Market cap
$66.75B
Enterprise value
$74.99B
Valuations
Price to earnings (P/E)
113.66
Price to book (P/B)
3.78
Price to sales (P/S)
5.31
EV/EBIT
55.22
EV/EBITDA
30.12
EV/Sales
5.97
Earnings
Revenue
$12.57B
EBIT
$1.36B
EBITDA
$2.49B
Free cash flow
$643M
Per share
EPS
$0.41
Free cash flow per share
$0.45
Book value per share
$12.32
Revenue per share
$8.78
TBVPS
$9.11
Balance sheet
Total assets
$31.95B
Total liabilities
$14.31B
Debt
$8.58B
Equity
$17.64B
Working capital
$1.6B
Liquidity
Debt to equity
0.49
Current ratio
1.45
Quick ratio
0.62
Net debt/EBITDA
3.31
Margins
EBITDA margin
19.8%
Gross margin
68.8%
Net margin
5.2%
Operating margin
11.7%
Efficiency
Return on assets
1.9%
Return on equity
3.5%
Return on invested capital
7.8%
Return on capital employed
4.8%
Return on sales
10.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BSX stock price

How has the Boston Scientific stock price performed over time
Intraday
1.04%
1 week
5.55%
1 month
11.14%
1 year
17.68%
YTD
9.7%
QTD
20.32%

Financial performance

How have Boston Scientific's revenue and profit performed over time
Revenue
$12.57B
Gross profit
$8.65B
Operating income
$1.48B
Net income
$652M
Gross margin
68.8%
Net margin
5.2%
Boston Scientific's net margin has decreased by 49% YoY and by 28% QoQ
Boston Scientific's net income has decreased by 44% YoY and by 26% QoQ
Boston Scientific's operating income has increased by 44% YoY
BSX's operating margin is up by 31% year-on-year

Growth

What is Boston Scientific's growth rate over time

Valuation

What is Boston Scientific stock price valuation
P/E
113.66
P/B
3.78
P/S
5.31
EV/EBIT
55.22
EV/EBITDA
30.12
EV/Sales
5.97
The P/E is 48% above the last 4 quarters average of 76.6 and 24% above the 5-year quarterly average of 91.5
The EPS has decreased by 47% YoY and by 28% from the previous quarter
The stock's price to book (P/B) is 14% less than its 5-year quarterly average of 4.4 but 11% more than its last 4 quarters average of 3.4
The equity has grown by 7% YoY and by 2.3% from the previous quarter
BSX's P/S is 11% above its last 4 quarters average of 4.8 and 6% above its 5-year quarterly average of 5.0
The revenue has increased by 10% YoY

Efficiency

How efficient is Boston Scientific business performance
The return on equity has declined by 49% year-on-year and by 29% since the previous quarter
The return on assets has declined by 46% year-on-year and by 27% since the previous quarter
The ROS has decreased by 23% YoY and by 18% from the previous quarter
BSX's ROIC is down by 17% from the previous quarter and by 15% YoY

Dividends

What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BSX.

Financial health

How did Boston Scientific financials performed over time
Boston Scientific's total assets is 123% more than its total liabilities
BSX's quick ratio is down by 31% year-on-year but it is up by 11% since the previous quarter
BSX's current ratio is up by 11% since the previous quarter but it is down by 6% year-on-year
Boston Scientific's debt is 51% lower than its equity
Boston Scientific's debt to equity has decreased by 11% YoY and by 6% from the previous quarter
The equity has grown by 7% YoY and by 2.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.